Allarity Therapeutics, Inc. Quarterly Deferred Income Tax Expense (Benefit) in USD from Q1 2021 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
Summary
Allarity Therapeutics, Inc. quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from Q1 2021 to Q1 2024.
  • Allarity Therapeutics, Inc. Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2024 was -$14K.
  • Allarity Therapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2023 was $97K.
  • Allarity Therapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2022 was -$1.61M, a 8160% decline from 2021.
  • Allarity Therapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2021 was $20K, a 87.9% decline from 2020.
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$14K Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q1 2022 -$1.23M -$1.26M -3818% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q1 2021 $33K Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-27
* An asterisk sign (*) next to the value indicates that the value is likely invalid.